Powered by: Motilal Oswal
13/10/2021 10:32:26 AM | Source: ICICI Direct
Hold Lupin Ltd For Target Rs.1025 - ICICI Direct
News By Tags | #872 #3961 #196 #642 #1302
Hold Lupin Ltd For Target Rs.1025 - ICICI Direct

India, milestone buoy numbers but US below-par

About the stock: Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.

* It is the third largest generic player (by prescriptions) in the US with 168 generic products (market leader: 52 products; Top 3: 122 products) along with being sixth largest company in Indian pharmaceutical market

* Lupin is the largest manufacturer of anti-TB drugs in the world and enjoys global leadership in anti-TB & Cephalosporins

 

Q1FY22 Results: Lupin reported decent Q1FY22 results.

* Sales were up 21% YoY to | 4270 crore

* EBITDA in Q1FY22 was at | 927 crore, up 90% YoY with margins at 21%

* Consequent adjusted PAT was at | 542 crore (up 407% YoY)

 

What should investors do? 

Lupin’s share price has de-grown by ~0.6x over the past five years (from ~| 1739 in July 2016 to ~| 1107 levels in July 2021).

* We retain HOLD rating on the stock

Target Price and Valuation: We value Lupin at | 1025 i.e. 22x P/E on FY23E EPS

 

Key triggers for future price performance:

* Its tie-ups with Eli Lilly, Boehringer for anti-diabetics and with MSD for pneumonia vaccines will help bolster domestic franchise

* Lupin plans to deepen its presence in Derma & women’s health segments apart from continued respiratory traction in the US

* Lupin’s US business comprises one of the largest ANDA pipelines that include 437 filed ANDAs and 149 pending approvals including 45 FTFs

 

Alternate Stock Idea: Apart from Lupin, in our healthcare coverage we like Cipla.

* Cipla is a global pharma company with over 1,500+ products in 65 therapeutic categories, with over 50 dosage forms

* BUY with a target price of | 1205

 

To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 

Above views are of the author and not of the website kindly read disclaimer

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here